DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hyper-IgM syndrome type 1 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHyper-IgM syndrome type 1 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hyper-igm syndrome type 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CD40 ligand (CD40LG) — CD40LG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet tmodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6W9G · 1.82 Å · ligand trimethylamine oxide (TMO). Experimental structure, not a prediction.
What the evidence adds up to
In 1994 the hallmark of hyper-IgM syndrome type 1 was described as an inability to switch from one immunoglobulin isotype to another. Patients present with recurrent bacterial infections including otitis media and pneumonia, plus opportunistic infections, recurrent neutropenia, lymphoid hyperplasia, and autoimmune manifestations. Serum immunoglobulins show low or absent IgG, IgA, and IgE with normal or elevated IgM and IgD. The syndrome can be X-linked or autosomal recessive.
A 2007 report described a 19-year-old male with X-linked hyper-IgM syndrome who developed progressive multifocal leukoencephalopathy. His serum IgA was decreased, IgM slightly increased, and IgG normal due to monthly immunoglobulin infusions. CD40 ligand expression on T cells was markedly reduced. Magnetic resonance imaging showed confluent lesions involving most of the right hemisphere with mass effect. The patient died after six weeks despite combined antiviral treatment. The authors concluded that progressive multifocal leukoencephalopathy may follow a rapid course in these patients because of global defects in cellular and B cell responses.
A 2024 case report described an infant whose hyper-IgM syndrome was revealed by persistent chronic neutropenia. The report reiterated that the condition is caused by a defect in B lymphocytes, with normal or high IgM and low or absent IgG, IgA, and IgE due to deficient isotype switching. Clinical manifestations are dominated by recurrent respiratory and digestive infections.
What is still missing are prospective trials that stratify patients by CD40 ligand expression or genetic subtype, and funding to test whether any existing drug can prevent the rapid neurological deterioration seen in some cases. No drug was mentioned in any of these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1994 · 41 citations · open access
Prenatal Diagnosis of X-Linked Hyper-IgM Syndrome
AbstractThe inability to initiate switching from one immunoglobulin isotype to another is the hallmark of the hyper-IgM immunodeficiency syndrome1. Patients with this primary immune disorder, originally termed “dysgammaglobulinemia type 1,”2 usually present with recurrent bacterial infections, including otitis media and pneumonia. Additional clinical features include opportunistic infections, recurrent neutropenia, lymphoid hyperplasia, and autoimmune manifestations. Abnormalities of serum immunoglobulins include low levels or an absence of IgG, IgA, and IgE and normal or, more frequently, elevated levels of IgM and IgD. The hyper-IgM syndrome can be inherited in an X-linked or autosomal recessive fashion. The candidate gene for this disease . . .
X-linked Hyper-IgM Syndrome Associated With a Rapid Course of Multifocal Leukoencephalopathy
AbstractOBJECTIVE: To report an exceptional association between X-linked hyper-IgM syndrome and progressive multifocal leukoencephalopathy. DESIGN: Clinical, immunological, and histological analysis. Patient A 19-year-old male patient with X-linked hyper-IgM syndrome developed typical signs and symptoms of progressive multifocal leukoencephalopathy. RESULTS: The serum level of IgA was decreased; the serum level of IgM was slightly increased; and the serum level of IgG was normal as a result of monthly infusions of immunoglobulin. The expression of CD40 ligand on T cells was markedly reduced in the patient. Magnetic resonance imaging indicated confluent lesions involving the majority of the right hemisphere with a mass effect. The patient died after 6 weeks despite combined antiviral treatment. CONCLUSION: Progressive multifocal leukoencephalopathy may follow a rapid course in patients with X-linked hyper-IgM syndrome because of global defects of cellular and B cell responses.
International Journal of Advanced Research · 2024 · 0 citations · open access
CHRONIC NEUTROPENIA REVEALING HYPER IGM SYNDROME: A CASE REPORT
AbstractHyper IgM syndrome is a well-knownhereditaryimmunodeficiency, first describedin 1961. It iscaused by a defect in B lymphocytes, characterized by a normal or high serumlevel of IgM and a low or zerolevel of IgG, IgA, IgE resultingfrom a deficiency in isotype switching. Itsclinical manifestations are dominated by recurrent infections, especiallyrespiratory and digestive. The interest of this article is to illustrate a particular mode of revelation of hyper IgM syndromes through persistent chronicneutropenia in an infant.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
